Want to see IN:GLAXO full AI Analyst Report?
Top Page
GlaxoSmithKline Pharmaceuticals Limited
(GLAXO)
Select Model
Select Model
Rating:77Outperform
Price Target:
₹2,729.00
▲(8.58% Upside)
Action:Upgraded
Date:08/17/26
The score is driven primarily by strong financial performance (improving profitability, minimal debt, and solid free cash flow quality) and supportive technical momentum (price above key moving averages with positive MACD). The main offset is valuation, with a high P/E that increases downside risk if growth or margins disappoint.
Positive Factors
Improving revenue and margins
The return to steady revenue growth after 2023, combined with materially stronger 2026 margins, indicates improving operating performance. If maintained, this mix of top-line recovery and operating leverage can support more durable earnings growth and strengthen the company’s ability to reinvest in its branded portfolio.
Negative Factors
Interrupted revenue trajectory
The 2023 revenue decline shows that the company’s top-line progression has not been uninterrupted. Although growth subsequently reaccelerated, the prior contraction raises the need for continued execution across its product portfolio and distribution channels to establish a consistently durable growth trajectory.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving revenue and margins
The return to steady revenue growth after 2023, combined with materially stronger 2026 margins, indicates improving operating performance. If maintained, this mix of top-line recovery and operating leverage can support more durable earnings growth and strengthen the company’s ability to reinvest in its branded portfolio.
Read all positive factors
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹420.73B
Dividend Yield2.29%
Average Volume (3M)3.99K
Price to Earnings (P/E)39.6
Beta (1Y)0.87
Revenue Growth5.75%
EPS Growth12.41%
CountryIN
Employees3,103
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)63.05
Shares Outstanding169,406,040
10 Day Avg. Volume2,257
30 Day Avg. Volume3,992
Financial Highlights & Ratios
PEG Ratio3.20
Price to Book (P/B)17.06
Price to Sales (P/S)10.12
P/FCF Ratio39.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.9
Revenue Forecast (FY)₹42.54B
GlaxoSmithKline Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescriptio...
How the Company Makes Money
GLAXO makes money primarily by selling pharmaceutical and healthcare products through domestic and institutional channels. Its core revenue stream is product sales: (1) prescription medicines sold to hospitals, clinics, and pharmacies via wholesal...
GlaxoSmithKline Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.55B | 38.22B | 37.26B | 34.42B | 32.26B | 32.64B |
| Gross Profit | 20.55B | 16.65B | 22.53B | 20.22B | 18.68B | 18.14B |
| EBITDA | 15.20B | 14.75B | 13.28B | 8.88B | 9.04B | 8.49B |
| Net Income | 10.68B | 10.36B | 9.28B | 5.90B | 6.11B | 16.95B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 43.24B | 41.08B | 35.57B | 33.27B | 46.33B |
| Cash, Cash Equivalents and Short-Term Investments | 27.57B | 27.56B | 24.98B | 18.57B | 16.54B | 29.03B |
| Total Debt | 0.00 | 332.70M | 99.50M | 186.65M | 155.40M | 200.76M |
| Total Liabilities | -22.67B | 20.56B | 21.57B | 17.79B | 15.85B | 19.70B |
| Stockholders Equity | 22.67B | 22.67B | 19.51B | 17.78B | 17.41B | 26.63B |
Cash Flow | ||||||
| Free Cash Flow | 1.67B | 9.67B | 12.67B | 5.51B | 4.40B | 7.76B |
| Operating Cash Flow | 1.84B | 10.22B | 12.90B | 5.82B | 4.84B | 8.11B |
| Investing Cash Flow | 3.40B | 2.78B | -458.10M | 87.12M | 8.08B | -4.06B |
| Financing Cash Flow | -7.23B | -7.37B | -7.69B | -5.61B | -15.43B | -5.24B |
GlaxoSmithKline Pharmaceuticals Limited Technical Analysis
Negative
2513.25
Price Trends
2766.10
Negative
2614.26
Negative
2485.41
Negative
Market Momentum
-77.92
Negative
37.88
Neutral
67.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAXO, the sentiment is Negative. The current price of 2513.25 is below the 20-day moving average (MA) of 2544.66, below the 50-day MA of 2766.10, and above the 200-day MA of 2485.41, indicating a bearish trend. The MACD of -77.92 indicates Negative momentum. The RSI at 37.88 is Neutral, neither overbought nor oversold. The STOCH value of 67.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GLAXO.
GlaxoSmithKline Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹543.84B | 33.74 | ― | 2.01% | 6.29% | 11.18% | |
79 Outperform | ₹1.11T | 38.44 | ― | 2.10% | -0.74% | -46.77% | |
77 Outperform | ₹420.73B | 39.56 | ― | 2.29% | 5.75% | 12.41% | |
77 Outperform | ₹168.67B | 22.95 | ― | 2.03% | 10.69% | -9.09% | |
65 Neutral | ₹511.12B | 45.19 | ― | 0.65% | 17.57% | 46.53% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,483.55
-75.69
-2.96%
IN:ABBOTINDIA
Abbott India Limited
25,593.30
-2,747.84
-9.70%
IN:CIPLA
Cipla Ltd
1,380.00
-107.68
-7.24%
IN:GLAND
Gland Pharma Ltd.
3,097.50
1,182.49
61.75%
IN:PFIZER
PFIZER LIMITED
3,687.05
-1,437.31
-28.05%
IN:SANOFICONR
Sanofi Consumer Healthcare India Limited
3,435.05
-1,307.75
-27.57%
GlaxoSmithKline Pharmaceuticals Limited Corporate Events
GSK Pharma Shareholders Approve Board and Managing Director Appointments via Postal Ballot
Sep 15, 2026
GlaxoSmithKline Pharmaceuticals Limited is a Mumbai-based pharmaceutical company focused on developing, manufacturing, and marketing prescription medicines and vaccines for the Indian market. The company operates within the broader healthcare and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.